Literature DB >> 31945035

Early Season Pediatric Influenza B/Victoria Virus Infections Associated with a Recently Emerged Virus Subclade - Louisiana, 2019.

Daniel Owusu, Julie Hand, Mark W Tenforde, Leora R Feldstein, Juliana DaSilva, John Barnes, Grace Lee, Juliet Tran, Theresa Sokol, Alicia M Fry, Lynnette Brammer, Melissa A Rolfes.   

Abstract

Multiple genetically distinct influenza B/Victoria lineage viruses have cocirculated in the United States recently, circulating sporadically during the 2018-19 season and more frequently early during the 2019-20 season (1). The beginning of the 2019-20 influenza season in Louisiana was unusually early and intense, with infections primarily caused by influenza B/Victoria lineage viruses. One large pediatric health care facility in New Orleans (facility A) reported 1,268 laboratory-confirmed influenza B virus infections, including 23 hospitalizations from July 31 to November 21, 2019, a time when influenza activity is typically low. During this period, Louisiana also reported one pediatric death associated with influenza B virus infection. An investigation of the influenza B virus infections in Louisiana, including medical and vaccine record abstraction on 198 patients, primarily from facility A, with sporadic cases from other facilities in the state, found that none of the patients had received 2019-20 seasonal influenza vaccine, in part because influenza activity began before influenza vaccination typically occurs. Among 83 influenza B viruses sequenced from 198 patients in Louisiana, 81 (98%) belonged to the recently emerged B/Victoria V1A.3 genetic subclade. Nationally, to date, B/Victoria viruses are the most commonly reported influenza viruses among persons aged <25 years (2). Of the 198 patients in the investigation, 95% were aged <18 years. Although most illnesses were uncomplicated, the number of hospitalizations, clinical complications, and the reported pediatric death in Louisiana serve as a reminder that, even though influenza B viruses are less common than influenza A viruses in most seasons, influenza B virus infection can be severe in children. All persons aged ≥6 months should receive an annual influenza vaccination if they have not already received it (3). Antiviral treatment of influenza is recommended as soon as possible for all hospitalized patients and for outpatients at high risk for influenza complications (including children aged <2 years and persons with underlying medical conditions) (4).

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31945035     DOI: 10.15585/mmwr.mm6902e1

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  9 in total

1.  Anomalous influenza seasonality in the United States and the emergence of novel influenza B viruses.

Authors:  Rebecca K Borchering; Christian E Gunning; Deven V Gokhale; K Bodie Weedop; Arash Saeidpour; Tobias S Brett; Pejman Rohani
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-02       Impact factor: 11.205

2.  A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial.

Authors:  Raffael Nachbagauer; Jodi Feser; Abdollah Naficy; David I Bernstein; Jeffrey Guptill; Emmanuel B Walter; Franceso Berlanda-Scorza; Daniel Stadlbauer; Patrick C Wilson; Teresa Aydillo; Mohammad Amin Behzadi; Disha Bhavsar; Carly Bliss; Christina Capuano; Juan Manuel Carreño; Veronika Chromikova; Carine Claeys; Lynda Coughlan; Alec W Freyn; Christopher Gast; Andres Javier; Kaijun Jiang; Chiara Mariottini; Meagan McMahon; Monica McNeal; Alicia Solórzano; Shirin Strohmeier; Weina Sun; Marie Van der Wielen; Bruce L Innis; Adolfo García-Sastre; Peter Palese; Florian Krammer
Journal:  Nat Med       Date:  2020-12-07       Impact factor: 53.440

3.  Pleiotropic Effects of Influenza H1, H3, and B Baloxavir-Resistant Substitutions on Replication, Sensitivity to Baloxavir, and Interferon Expression.

Authors:  Brady T Hickerson; Simone E Adams; Subrata Barman; Lance Miller; Vladimir Y Lugovtsev; Richard J Webby; William L Ince; Raymond P Donnelly; Natalia A Ilyushina
Journal:  Antimicrob Agents Chemother       Date:  2022-03-09       Impact factor: 5.938

4.  Influenza Vaccine Effectiveness for Prevention of Severe Influenza-Associated Illness Among Adults in the United States, 2019-2020: A Test-Negative Study.

Authors:  Carlos G Grijalva; Leora R Feldstein; H Keipp Talbot; Michael Aboodi; Adrienne H Baughman; Samuel M Brown; Jonathan D Casey; Heidi L Erickson; Matthew C Exline; D Clark Files; Kevin W Gibbs; Adit A Ginde; Michelle N Gong; Natasha Halasa; Akram Khan; Christopher J Lindsell; Samuel K Nwosu; Ithan D Peltan; Matthew E Prekker; Todd W Rice; Nathan I Shapiro; Jay S Steingrub; William B Stubblefield; Mark W Tenforde; Manish M Patel; Wesley H Self
Journal:  Clin Infect Dis       Date:  2021-10-20       Impact factor: 9.079

Review 5.  Reverse genetics for influenza B viruses and recent advances in vaccine development.

Authors:  Stivalis Cardenas-Garcia; C Joaquin Caceres; Daniela Rajao; Daniel R Perez
Journal:  Curr Opin Virol       Date:  2020-11-27       Impact factor: 7.090

6.  Differential Expression of Serum Exosome microRNAs and Cytokines in Influenza A and B Patients Collected in the 2016 and 2017 Influenza Seasons.

Authors:  Sreekumar Othumpangat; William G Lindsley; Donald H Beezhold; Michael L Kashon; Carmen N Burrell; Samira Mubareka; John D Noti
Journal:  Pathogens       Date:  2021-02-02

7.  Effect of Antigenic Drift on Influenza Vaccine Effectiveness in the United States-2019-2020.

Authors:  Mark W Tenforde; Rebecca J Garten Kondor; Jessie R Chung; Richard K Zimmerman; Mary Patricia Nowalk; Michael L Jackson; Lisa A Jackson; Arnold S Monto; Emily T Martin; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Arundhati Rao; Sara S Kim; Thomas J Stark; John R Barnes; David E Wentworth; Manish M Patel; Brendan Flannery
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 20.999

8.  Characterization of Influenza A and B Viruses Circulating in Southern China During the 2017-2018 Season.

Authors:  Yuqian Yan; Junxian Ou; Shan Zhao; Kui Ma; Wendong Lan; Wenyi Guan; Xiaowei Wu; Jing Zhang; Bao Zhang; Wei Zhao; Chengsong Wan; Weifeng Shi; Jianguo Wu; Donald Seto; Zhiwu Yu; Qiwei Zhang
Journal:  Front Microbiol       Date:  2020-05-29       Impact factor: 5.640

9.  Cell-Adapted Mutations and Antigenic Diversity of Influenza B Viruses in Missouri, 2019-2020 Season.

Authors:  Cynthia Y Tang; Karen Segovia; Jane A McElroy; Tao Li; Minhui Guan; Xiaojian Zhang; Shamita Misra; Jun Hang; Xiu-Feng Wan
Journal:  Viruses       Date:  2021-09-22       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.